Anti-inflammatory therapy cuts risk of lung cancer

In most clinical trials for cancer therapy, investigators test treatments in patients with advanced disease. But a recent cardiovascular secondary prevention study has given researchers a unique opportunity: to explore the effectiveness of giving a drug to patients before cancer emerges. At the European Society of Cardiology meeting, Paul M. Ridker, MD, director of the Center for Cardiovascular Disease Prevention at BWH, and colleagues presented findings from CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Related Links:

Although thoracoscopic left atrial appendectomy has been recently developed as an effective method for preventing cardiogenic thromboembolism,1 the application of this operation is still limited. In thoracoscopic left upper lobectomy, the surgical site is quite similar to that of thoracoscopic left atrial appendectomy, so combined surgery is feasible. When patients with indications for left upper lobectomy (eg, for lung cancer) have had the preoperative complication of atrial fibrillation, we have assumed that additional left atrial appendectomy is acceptable.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Adult: Arrhythmias: Letter to the editor Source Type: research
Superior vena cava syndrome occurs from obstruction of the superior vena cava. The most common cause is malignancy. Small cell lung cancer and non-Hodgkin lymphoma are the most frequent culprits. Intravascular devices associated with thrombus are becoming more common causes. Classic symptoms include edema, plethora, and distended veins of the face, neck, and chest; shortness of breath; cough; headache; and hoarseness. Treatment in the emergency department is mostly supportive, with head elevation, oxygen, and steroids. Rarely, emergent airway issues and cerebral edema must be addressed. Definitive treatment includes radiot...
Source: Emergency Medicine Clinics of North America - Category: Emergency Medicine Authors: Source Type: research
I, Ay C Abstract In contrast to venous thromboembolism, little is known about arterial thromboembolism in patients with cancer. The aim of this study was to quantify the risk and explore clinical risk factors of arterial thromboembolism in patients with cancer, and investigate its potential impact on mortality. Patients with newly-diagnosed cancer or progression of disease after remission were included in a prospective observational cohort study and followed for 2 years. Between October 2003 and October 2013, 1880 patients (54.3% male; median age: 61 years) were included. During a median follow-up of 723 days, 48 ...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Authors: Suzuki K, Yanagimura T, Ohashi K, Kagamu H, Takada T Abstract A 65-year-old man was diagnosed with advanced non-small, non-squamous lung cancer. He was treated with chemotherapy containing bevacizumab as well as cisplatin and pemetrexed. After 2 courses of treatment, computed tomography revealed that his abdominal aortic artery was almost occluded by a thrombus; however, he had no ischemic symptoms. Heparin infusion and warfarin reduced the size of the arterial thrombus and the patient was subsequently treated with chemotherapy without bevacizumab. No thrombotic events occurred during the subsequent treatm...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Preclinical data suggest that oncogene (EGFR and KRAS) events regulate tumor procoagulant activity. However, few studies have prospectively investigated the clinical relevance between the presence of EGFR or K...
Source: Respiratory Research - Category: Respiratory Medicine Authors: Tags: Research Source Type: research
Metastatic non-small cell lung cancer (NSCLC) is a recognized risk factor for VTE. Some systemic treatments may increase this risk further. Here, we present the risk of VTE and its prognostic significance for patients treated with chemotherapy (chemo) and the EGFR monoclonal antibody necitumumab (neci) for metastatic NSCLC.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Full Length Article Source Type: research
Rationale: Acute thrombosis has not been reported in the literature so far in lung cancer patients as an immune-related adverse event (irAE) associated with PD-1 pathway inhibitors. Patients concerns: Here, we for the first time present two NSCLC (non-small cell lung cancer) patients suffering from acute thrombosis as a pembrolizumab-induced irAE. Immediate treatment with continuous heparin infusion improved their symptoms and enabled them to continue pembrolizumab administration. Methods: Ethical approval was given by the ethics committee of Osaka International Cancer Institute and the informed consents were given...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
This study aimed to investigate the effects and complications of different types of peripherally inserted central catheters through femoral vein catheterization in patients with lung cancer undergoing chemotherapy. METHODS: A retrospective analysis of 158 patients with lung cancer undergoing implantation of a venous access through femoral vein catheterization was performed. The patients were divided into two groups by convenience sampling: the single-lumen silicone Groshong peripherally inserted central catheters with valved tip were used in patients in group A, the single-lumen power-injectable polyurethane peripheral...
Source: The Journal of Vascular Access - Category: Surgery Tags: J Vasc Access Source Type: research
Conclusions—Our findings indicate that cancer cell type is associated with circulating EV levels and coagulopathy in patients with lung cancer and stroke.
Source: Stroke - Category: Neurology Authors: Tags: Biomarkers, Mechanisms, Translational Studies, Cerebrovascular Disease/Stroke, Thrombosis Brief Reports Source Type: research
Conclusions Significant proportions of VTE events occur after hospital discharge. Although there are data to suggest that the risk for VTE extends beyond this period, few patients are managed with postdischarge prophylaxis. These data suggest that postdischarge prophylaxis should be considered for those patients at high risk for VTE, particularly for older patients, those who are obese, and after extended or lengthy resections.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular | Clinical Trials | Heart | Lung Cancer | Pharmaceuticals | Study | Thrombosis